On Jul. 13, 2022, Novavax announced that its COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) had received emergency use authorization from the Food and Drug Administration to provide a two-dose primary series for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and over.

Doses of the Novavax COVID-19 Vaccine, Adjuvanted were shipped from the Serum Institute of India, the world’s largest vaccine manufacturer by volume, and were in the U.S. The next step for the vaccine was a policy recommendation for use from the Centers for Disease Control and Prevention (CDC).